<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575012</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-STEMI 24-48</org_study_id>
    <nct_id>NCT04575012</nct_id>
  </id_info>
  <brief_title>Compare Early With Deferred Invasive Strategy for STEMI Presenting 24-48 Hours From Symptom Onset</brief_title>
  <official_title>A Randomized Multicentre Trial to Compare Early With Deferred Invasive Strategy for Patients With Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours From Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to compare the efficacy of early with deferred invasive&#xD;
      strategy for patients with ST-segment elevation myocardial infarction (STEMI) within 24-48h&#xD;
      of symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, timely primary percutaneous coronary intervention (PCI) is the preferred strategy&#xD;
      for STEMI patients within 24h of symptom onset. In stable STEMI patients presenting 12 to 48&#xD;
      hours from symptom onset, BRAVE-2 Trial (n = 365) showed improved myocardial salvage and&#xD;
      4-year survival in patients treated with primary PCI compared with conservative treatment&#xD;
      alone. However, data is scarce about the reperfusion strategy focusing on STEMI patients&#xD;
      within 24-48h of symptom onset.&#xD;
&#xD;
      To our knowledge, due to the long onset time and insufficient antiplatelet/anticoagulant&#xD;
      treatment, infarct-related artery in STEMI patients beyond 24h of symptom onset frequently&#xD;
      suffer from severer thrombus burden. In this situation, the risk of no-reflow in primary PCI&#xD;
      is high. Meanwhile, myocardial coagulative necrosis would be fully developed during 24-72h&#xD;
      from symptom onset, the risk of perioperative cardiac rupture may also rise. These bring some&#xD;
      doubts about the benefits of early invasive strategy for STEMI patients within 24-48h of&#xD;
      symptom onset. Further investigations are warranted to explore the best timing of invasive&#xD;
      strategy for STEMI patients within 24-48h of symptom onset.&#xD;
&#xD;
      Given that no randomized clinical trial is designed especially for STEMI patients within&#xD;
      24-48h of symptom onset, and limited data is available to compare early with deferred&#xD;
      invasive strategy for the subgroup of STEMI patients, investigators plan to perform a&#xD;
      controlled, randomized trial to compare the efficacy of early with deferred invasive strategy&#xD;
      for STEMI patients within 24-48h of symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of death from any cause, recurrent myocardial infarction, ischaemia-driven target vessel revascularization, or hospitalization due to NYHA class IV heart failure</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No-reflow in infarct-related artery</measure>
    <time_frame>Immediately after PCI</time_frame>
    <description>The definition of no-reflow was Thrombolysis In Myocardial Infarction (TIMI) flow grade ≤ 2 on the final angiogram in a coronary angiographic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (defined as a composite of cardiac death, recurrent myocardial infarction, or ischaemia-driven target vessel revascularization)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>The diagnosis of stroke required confirmation by computed tomography or magnetic resonance imaging of the head in the presence of a new onset focal or global neurological deficit lasting more than 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent myocardial infarction</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemia-driven target vessel revascularization</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to NYHA class IV heart failure</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction (STEMI)</condition>
  <arm_group>
    <arm_group_label>Deferred invasive strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Early invasive strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deferred invasive strategy</intervention_name>
    <description>PCI on 7 to 10 days after symptom onset</description>
    <arm_group_label>Deferred invasive strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early invasive strategy</intervention_name>
    <description>Primary PCI</description>
    <arm_group_label>Early invasive strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 or over and less than 75 years old;&#xD;
&#xD;
          2. ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment&#xD;
             elevation in 2 contiguous extremity leads;&#xD;
&#xD;
          3. Patents with STEMI with symptom onset between 24 and 48 hours before randomization;&#xD;
&#xD;
          4. Signed informed consent form prior to trial participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patents with STEMI with symptom onset &lt;24h or &gt;48h or uncertain time onset;&#xD;
&#xD;
          2. Prior administration of thrombolytic therapy or attempted PCI before randomization;&#xD;
&#xD;
          3. Presence of indications for primary PCI, such as persistent chest pain, cardiogenic&#xD;
             shock, life-threatening arrhythmias or cardiac arrest, severe acute heart failure, and&#xD;
             mechanical complications;&#xD;
&#xD;
          4. Coagulopathy, active peptic ulcer, history of cerebral or subarachnoid hemorrhage,&#xD;
             stroke within 6 months, other contraindications for antiplatelet or anticoagulant&#xD;
             therapy;&#xD;
&#xD;
          5. Known intolerance to antiplatelet (e.g. aspirin, clopidogrel, ticagrelor) and&#xD;
             anticoagulant therapy (e.g. heparin, bivalirudin);&#xD;
&#xD;
          6. Congenital heart disease or severe valvular disease;&#xD;
&#xD;
          7. eGFR &lt;30 ml/min/1.73 m2;&#xD;
&#xD;
          8. History of malignant tumors;&#xD;
&#xD;
          9. Combined with other diseases and life expectancy ≤12 months;&#xD;
&#xD;
         10. Pregnancy;&#xD;
&#xD;
         11. Inclusion in another clinical trial;&#xD;
&#xD;
         12. Inability to provide informed consent or not available for follow-up judged by&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Zhong, M.D.</last_name>
    <phone>+86 13585678706</phone>
    <email>zhong.xin@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Gao, M.D.</last_name>
    <phone>+86 13661959824</phone>
    <email>gao.wei1@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST-segment Elevation Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Invasive Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

